Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The approach is called an in situ vaccine because it uses something in the body (in situ)—here, a tumor—to help create an immune response.
“The simplicity of this approach means that it is promising to take forward” to a human vaccine, researchers say.
Many vaccines are preventive. This is a THERAPEUTIC vaccine: it teaches your immune system to recognize the problem AFTER you have it.
The vaccine, based on an individual’s own tumor cells, improved survival time and proved safe in an early-stage trial.
In a small clinical trial, the vaccine trained the immune system to recognize tumors and attack them in people with lymphoma.
INVAC-1 vaccine targets the telomerase enzyme involved in cancer cell growth.
Vaccine has the potential to prevent 90 percent of HPV-related cancers.
Customized immunotherapy targets receptor found in some breast, colorectal, lung, ovarian, prostate and gastroesophageal cancers.
Matthias Stephan, MD, PhD, receives grant to develop cancer vaccine–optimizing, TCR-programming nanotechnology.
Future clinical trials will explore whether cellular and antibody-based therapies can be beneficial as earlier-stage treatments.
As our understanding of the molecular basis of disease rises, doctors and researchers gain greater insight into individual patient needs.
Activating T cells in tumors eliminated even distant metastases in mice, Stanford researchers found.
Individually tailored vaccines help T cells recognize tumors.
More than 40 percent of cancers are caused by factors we can control.
Individually designed vaccines help T cells recognize specific markers on tumor cells
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.